A citation-based method for searching scientific literature

S Sha, D Polidori, T Heise, J Natarajan, K Farrell, S-S Wang, D Sica, P Rothenberg, L Plum-Mörschel. Diabetes Obes Metab 2014
Times Cited: 143



Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani, Ralph A DeFronzo. J Clin Invest 2014
Times Cited: 474




List of shared articles



Times cited


Combination therapy with SGLT2 inhibitors for diabetic kidney disease.
Yuwen Cai, Xin Liu, Gaosi Xu. Biomed Pharmacother 2020
4


Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation.
Tomoko Yamada, Kazuhiko Sakaguchi, Yuko Okada, Hiroshi Miura, Natsu Otowa-Suematsu, Anna So, Hisako Komada, Yushi Hirota, Takeshi Ohara, Yasuo Kuroki,[...]. Diabetol Int 2020
0

Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy.
Riobaldo Cintra, Filipe A Moura, Luis Sergio F de Carvalho, Joaquim Barreto, Marcos Tambascia, Roberto Pecoits-Filho, Andrei C Sposito. Rev Assoc Med Bras (1992) 2019
10

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control.
Manash Pratim Baruah, B M Makkar, Vikrant B Ghatnatti, Kaushik Mandal. Indian J Endocrinol Metab 2019
5

Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research.
Amber L Beitelshees, Bruce R Leslie, Simeon I Taylor. Diabetes 2019
16

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.
Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami, Kunio Hieshima, Akira Yoshida, Katsunori Jinnouchi, Hiroyuki Nishimura, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara,[...]. J Atheroscler Thromb 2018
32

Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
Robert Martinez, Hussein Al-Jobori, Ali M Ali, John Adams, Muhammad Abdul-Ghani, Curtis Triplitt, Ralph A DeFronzo, Eugenio Cersosimo. Diabetes 2018
33




An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.
Joseph A Messana, Stanley S Schwartz, Raymond R Townsend. Vasc Health Risk Manag 2017
5

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Honghong Zou, Baoqin Zhou, Gaosi Xu. Cardiovasc Diabetol 2017
39